Floatz logo

Tiagabine

Focal Epilepsy

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Small moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Focal Epilepsy cohort.

Asset / SponsorPhaseRating
Eslicarbazepine Acetate
Sumitomo Pharma America, Inc.
Phase 4A
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4A
Topamax
Mario Negri Institute for Pharmacological Research
Phase 4A
Lacosamide
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 4A
Oxcarbamezapine
Mario Negri Institute for Pharmacological Research
Phase 4A

View all 50 →

Same molecule, other indications

Tiagabine is also rated in:

Mental RetardationDormant
BB
Indicative ·
65 / 100
View asset →
epilepsyDormant
B
Indicative ·
59 / 100
View asset →
schizophreniaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →